Eslicarbazepine acetate: A novel therapeutic alternative in the treatment of focal seizures;Acetato de eslicarbazepina: Una nueva alternativa en el tratamiento de las crisis focales

Revista de Neurologia

Volumn 54, Issue 9, 2012, Pages 551-555

  Mauri Llerda, José A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Antiepileptic drugs; Epilepsy; Eslicarbazepine; Eslicarbazepine acetate; Oxcarbazepine; Refractory epilepsy; S licarbazepine

Indexed keywords

ESLICARBAZEPINE ACETATE;

ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FOCAL EPILEPSY; FOLLOW UP; HUMAN; NERVE CELL; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 84862087214     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5409.2012165     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Prevalence of self-reported epilepsy: United States, 1986-1990. JAMA 1994; 272: 1893.
2. Elger DC, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008; 12: 501-539.
3. Gil-Nagel A, Marín H. Lacosamida: una nueva generación en el tratamiento de la epilepsia. Rev Neurol 2011; 52: 159-162.
4. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007; 4: 88-96.
5. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady state pharmacokinetics of eslicarbazepine acetate(BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005; 45: 1062-1066.
6. Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In Shorvon S, Perucca E, Engel J, eds. Te treatment of epilepsy. 3 ed. Oxford, UK: Blackwell; 2009. p. 485-498.
7. Agencia Europea del Medicamento. Zebinix ® (acetato de eslicarbazepina): fcha técnica o resumen de las características del producto (actualizado en 2011). URL: http://www.ema. europa.eu/docs/es_ES/document_library/EPAR_Product_ Information/human/000988/WC500047225.pdf. [05.03.2012].
8. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter MA. Efect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ter 2008; 46: 119-130.
9. Almeida L, Potgieter JH, Maia J, Porgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008; 64: 267-273.
10. McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009; 23: 71-79.
11. Mestre T, Ferreira JJ. Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opin Investig Drugs 2009; 18: 221-229.
12. Bonifacio MJ, Sheridan RD, Parada A, Cunha A, Patmore L, Soares-da-Silva P. Interaction of novel anticonvulsivant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600-608.
13. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007; 48: 497-504.
14. Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P. Efcacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-463.
15. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010; 89: 278-285.
16. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efcacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-287.
17. Halász P, Cramer JA, Hodoba D, Członkowska A, Guekht A, Maia J, et al. Long-term efcacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010; 51: 1963-1969.
18. Gabbai A, Ben-Menachem E, Maia J, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of one-year open-label extension of study BIA-2093-302. Epilepsia 2008; 49 (Suppl 7): S432-S433.
19. Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. Long term treatment of partial epilepsy with eslicarbezepine acetate (ESL): results of one-year open-label extension of study BIA-2093-303. Epilepsia 2008; 49 (Suppl 7): S441-S442.
20. Hufnagel A, Ben-Menachem E, Gabbai AA, Maia J, Almeida L, Soares-da-Silva P. Efcacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 Study. Epilepsia 2009; 50: 104.
21. Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. Efcacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303. Epilepsia 2009; 50: 106.
22. Herranz-Fernández JL. Nuevas perspectivas en el tratamiento farmacológico de las epilepsias. Antiepilépticos de tercera generación. In Organización Médica Colegial, eds. Evidencia científca en epilepsia. Manual de actuación. Madrid: IMC; 2010. p. 125-135.
23. Landmark CH, Johannessen SI. Eslicarbazepine acetate. In Panayiotopoulos C P, ed. Atlas of epilepsies. London: Springer-Verlag; 2010. p. 1737-1739.